October 2023 Content Release Copied

10/26/20232023 ContentContent releasePhysician, Clinical, Admin, Billing

Lab Analytes & Panels

Additions

  • EJ Ab, SI
  • JO-1 AB, SI
  • MDA-5 Ab, SI
  • Mi-2 alpha Ab, SI
  • Mi-2 beta Ab, SI
  • NXP-2 Ab, SI
  • OJ Ab, SI
  • PL-12 Ab, SI
  • PL-7 Ab, SI
  • SRP Ab, SI
  • TIF-1 gamma Ab, SI

Medications

Additions

  • AAA617 (Lutetium (177Lu) vipivotide tetraxetan) invest IV
  • AZD2936 invest IV
  • BMF-500 invest Oral
  • CJC-1295 Acetate Oral
  • Ezabenlimab invest (BI 754091 invest IV)
  • Gallium (68Ga) gozetotide invest (68Ga-PSMA-11 invest IV)
  • HLX10 invest IV
  • Ivonescimab invest IV
  • Ivonescimab or pembrolizumab invest IV
  • MEDI5752 invest IV
  • Melanotan II Subcutaneous
  • NDI-101150 invest Oral
  • PHE885 invest IV
  • Pirtobrutinib invest (LOXO-305 invest Oral)
  • Sermorelin Acetate Subcutaneous
  • Sermorelin-Ipamorelin Compound Oral
  • Sermorelin-Ipamorelin Compound Subcutaneous

Updates

Medication Update
BI 1810631 invest Oral New Forms are now available:

  • 15 mg tablet
  • 60 mg tablet
Deferasirox Oral (Jadenu) New Maximum Single Dose is now available:

  • 4200 mg

New default Sig is now available:

  • 720 mg orally daily

New Instructions are now available:

  • Take on an empty stomach or with a light meal (around 250 calories with less than 7% fat). Do not take with aluminum-containing antacids.
Deferasirox Oral Granules (Jadenu) New Maximum Single Dose is now available:

  • 4200 mg

New default Sig is now available:

  • 720 mg orally daily

New Instructions are now available:

  • Sprinkle granules onto soft food (e.g. yogurt or applesauce) and take by mouth. Do not take with aluminum-containing antacids.
momelotinib Oral New Maximum Single Dose is now available:

  • 200 mg

New default Sig is now available:

  • 200 mg orally daily

New Instructions are now available:

  • Take with or without food.
motixafortide Subcutaneous New Rounding Rule is now available:

  • 1 mg

New Maximum Single Dose is now available:

  • 188 mg

New default Sig is now available:

  • 1.25 mg/kg subcutaneously once

New Instructions are now available:

  • Refer to prescribing information for recommendations for premedications, dosing, and administration. Filgrastim product must be administered on Days 1-4 prior to administration of motixafortide on the evening of Day 4. Calculate dose using actual body weight. Administer via slow subcutaneous injection (over approximately 2 minutes) 10 to 14 hours prior to initiation of apheresis. Injection volume should not exceed 2 mL. Divide doses requiring greater than 2 mL equally into multiple syringes. Inject into the abdomen, the back or side of upper arms, or thigh. If injecting into the abdomen, avoid a 5 cm diameter circle around the navel. If multiple injections are required, injection sites should be at least 2 cm apart. Do not inject into scar tissue or areas where the skin is reddened, inflamed, or swollen. Observe patient for 1 hour after administration.
Narazaciclib invest (ON 123300 invest Oral) New Forms are now available:

  • 40 mg tablet
  • 120 mg tablet
Nivolumab-Relatlimab-rmbw IV 240 mg-80 mg/20 mL New Sigs are now available:

  • 160 mg intravenously Piggyback once
  • 160 mg intravenously Piggyback As Directed
  • 480 mg intravenously Piggyback once
  • 480 mg intravenously Piggyback As Directed

New Default Sig is now available:

  • 480 mg intravenously Piggyback once
NUV-868 invest Oral New Forms are now available:

  • 40 mg tablet
  • 160 mg tablet
Quaratusugene ozeplasmid invest (GPX-001 invest IV) New Forms are now available:

  • 0.675 mg/1.5 mL solution
TH1902 invest IV New Unit is now available:

  • Mg/kg

Regimen Library

Additions

Regimen Name Diagnosis
Daratumumab IV + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D Multiple Myeloma (MM)
Daratumumab IV + Lenalidomide D1-21 Q28D (Post-Transplant Maintenance) Multiple Myeloma (MM)
Daratumumab SQ + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D Multiple Myeloma (MM)
Daratumumab SQ + Lenalidomide D1-21 Q28D (Post-Transplant Maintenance) Multiple Myeloma (MM)
Fulvestrant (Q28D) + Trastuzumab IV (Q21D) Q84D Breast Cancer
Fulvestrant Q28D (Uterine) Uterine Cancer (Parent)
Megestrol Q30D (Uterine) Uterine Cancer (Parent)
Momelotinib Q30D Myelofibrosis
Motixafortide D4 + Filgrastim D1-5 Multiple Myeloma
Nadofaragene firadenovec-vncg (Intravesical) Q90D Bladder Cancer
Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D (Neoadjuvant NSCLC) Lung Cancer, Non-small Cell (NSCLC)
Nivolumab D1,15,29 + Ipilimumab Q42D (Perioperative Esophageal, Gastric) Esophageal Cancer (Parent); Gastric Cancer
Nivolumab Q28D (Flat Dose) (Perioperative Esophageal, Gastric) Esophageal Cancer (Parent); Gastric Cancer
Panitumumab D1,15 + Adagrasib Q28D Colon Cancer; Rectal Cancer
Panitumumab D1,15 + Sotorasib Q28D Colon Cancer; Rectal Cancer
Pembrolizumab (Dose Banding) + Abraxane

+ Carboplatin Q42D

 Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab (Dose Banding) + Pemetrexed + Cisplatin Q42D Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab + Gemcitabine D1,8 + Cisplatin Q21D Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab Q21D (Flat Dose) (Perioperative NSCLC) Lung Cancer, Non-small Cell (NSCLC)
Tremelimumab-actl D1 + Durvalumab D1,29,57 (Esophageal, Gastric) Esophageal Cancer (Parent); Gastric Cancer

Updates

Antiemetic Prophylaxis

To improve ease of ordering antiemetic prophylaxis, a prechecked prescription order for oral ondansetron will be included in all regimens containing a moderate to high emetic risk oral oncolytic agent, per NCCN Guidelines. As an exception, oral oncolytic agents with risk for QT prolongation and therefore potential additive toxicity with ondansetron, will not have ondansetron prechecked.

This month will conclude applicable updates.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Amyloidosis
  • Bladder Cancer
  • Breast Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gastric Cancer
  • Leukemia, Acute Myeloid (AML)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Multiple Myeloma (MM)
  • Ovarian and Primary Peritoneal Cancer
  • Prostate Cancer
  • Renal Pelvis and Ureter Cancer
  • Urethral Cancer

Renames

Previous Name New Name
Cytarabine + Daunorubicin + Midostaurin Induction Cytarabine CIV D1-7 + Daunorubicin D1-3 + Midostaurin D8-21 (Induction) Q28D
Megestrol Q30D Megestrol Q30D (Breast)

Research

Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instructions Other Changes
USOR 18283 X X X
USOR 19062 No longer available:

USOR 19062 Safety Run-In Tazemetostat BID Maintenance USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV BIOSIMILAR Q28D
USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV Q28D Reference

Now available:

USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV Q28D
USOR 20270 X X No longer available:

USOR 20270 Pemetrexed Premedications
USOR 20270 Pembrolizumab + Pemetrexed + Cisplatin Q21D USOR 20270 Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 20270 Pembrolizumab + Pemetrexed Maintenance Q21D USOR 20270 Pembrolizumab + Pemetrexed D1,22 Maintenance Q42D

USOR 20270 MRTX849 (PO; BID) Monotherapy

Now available:

USOR 20270 Pembrolizumab Q21D USOR 20270 Pembrolizumab Q42D
USOR 20423 X X X
USOR 21326 X X Now available:

USOR 21326 Part 2 Bemarituzumab or Placebo + Nivolumab + CAPOX Q21D
USOR 22166 X X X
USOR 22181 X X
USOR 22232 X X X
USOR 22252 X X
USOR 23007 X X X
USOR 23031 X

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Donislecel-jujn (Lantidra) J3590 per 4500 EIN
Motixafortide (Aphexda) J3490 per 1.25 mg